rs113382419 - FAM163B
Magnitude 2.2 · 2 studies on file
Reported associations
-
Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study - Unknown journal (n.d.) · Unknown authors · PubMed 31689377
ABSTRACT: Background Smoking prevalence is higher amongst individuals with schizophrenia and depression compared with the general population. Mendelian randomisation (MR) can examine whether this association is causal using genetic variants identified in genome-wide association studies (GWAS). Methods We conducted two-sample MR to explore the bi-directional effects of smoking on schizophrenia and depression. For smoking behaviour, we used (1) smoking initiation GWAS from the GSCAN consortium and (2) we conducted our own GWAS of lifetime smoking behaviour (which captures smoking duration, heaviness and cessation) in a sample of 462690 individuals from the UK Biobank. We validated this instrument using positive control outcomes (e.g. lung cancer). For schizophrenia and depression we used GWA
-
Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals - Unknown journal (n.d.) · Unknown authors · PubMed 33082346
ABSTRACT: Here we report a large genome-wide association study (GWAS) for longitudinal smoking phenotypes in 286,118 individuals from the Million Veteran Program (MVP) where we identified 18 loci for smoking trajectory of current versus never in European Americans, one locus in African Americans, and one in Hispanic Americans. Functional annotations prioritized several dozen genes where significant loci co-localized with either expression quantitative trait loci or chromatin interactions. The smoking trajectories were genetically correlated with 209 complex traits, for 33 of which smoking was either a causal or a consequential factor. We also performed European-ancestry meta-analyses for smoking status in the MVP and GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN) (Ntotal
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Medication-assisted smoking cessation approach Moderate
Genetic predisposition to smoking-related traits may respond better to medication-assisted cessation strategies.
Discuss pharmacotherapy options for smoking cessation with healthcare provider.
Lifestyle
-
Enhanced smoking cessation support program High
C allele associated with reduced smoking cessation success and higher lifetime smoking burden; genetic predisposition may require additional behavioral and pharmacological support.
Engage with professional cessation program using structured behavioral therapy combined with pharmacotherapy.